Excretion, metabolism, and pharmacokinetics of 1-(8-(2- chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4- (ethylamino)piperidine-4- carboxamide, a selective cannabinoid receptor antagonist, in healthy male volunteers

Drug Metabolism and Disposition

Volumn 40, Issue 3, 2012, Pages 568-578

  Miao, Zhuang ^a   Sun, Hao ^a   Liras, Jennifer ^a   Prakash, Chandra ^a,b  

^a PFIZER INC   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CE 156706; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; OTENABANT; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONJUGATION; DRUG ABSORPTION; DRUG DISPOSITION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; FECES; HUMAN; HUMAN EXPERIMENT; HYDROLYSIS; HYDROXYLATION; IN VITRO STUDY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DOCKING; NORMAL HUMAN; PRIORITY JOURNAL; RADIOACTIVITY; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE;

ADULT; AMIDES; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FECES; HUMANS; HYDROLYSIS; HYDROXYLATION; MALE; MICROSOMES, LIVER; MIDDLE AGED; OXIMES; PIPERIDINES; PURINES; RECEPTOR, CANNABINOID, CB1; YOUNG ADULT;

EID: 84863416296     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.043273     Document Type: Article

References (32)

1. Akbas F, Gasteyger C, Sjödin A, Astrup A, and Larsen TM (2009) A critical review of the cannabinoid receptor as a drug target for obesity management. Obes Rev 10:58-67.
2. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, and Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berlin) 132:104-106. (Pubitemid 27303746)
3. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, and Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196.
4. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, and Gessa GL (1998) Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63:PL113-PL117.
5. Daly AK (2006) Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 45:13-31.
6. Di Marzo V (2008) CB(1) receptor antagonism: biological basis for metabolic effects. Drug Discov Today 13:1026-1041.
7. Di Marzo V and Matias I (2005) Endocannabinoid control of food intake and energy balance. Nat Neurosci 8:585-589. (Pubitemid 40594198)
8. Domanski TL, Finta C, Halpert JR, and Zaphiropoulos PG (2001) cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 59:386-392. (Pubitemid 32108573)
9. Griffith DA, Hadcock JR, Black SC, Iredale PA, Carpino PA, DaSilva-Jardine P, Day R, DiBrino J, Dow RL, Landis MS, et al. (2009) Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)--purin-6-Yl]-4-ethylaminopiperidine- 4-carboxylic acid amine hydrochloride (CP-945,598), a novel, potent and selective cannabinoid type 1 receptor antagonist. J Med Chem 52:234-237.
10. Hadcock JR, Griffith DA, Iredale PA, Carpino PA, Dow RL, Black SC, O'Connor R, Gautreau D, Lizano JS, Ward K, et al. (2010) In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity. Biochem Biophys Res Commun 394:366-371.
11. Halkier BA, Olsen CE, and Møller BL (1989) The biosynthesis of cyanogenic glucosides in higher plants. The (E)- and (Z)-isomers of p-hydroxyphenylacetaldehyde oxime as intermediates in the biosynthesis of dhurrin in Sorghum bicolor (L.) Moench.J Biol Chem 264:19487-19494. (Pubitemid 20008049)
12. Hildebrandt AL, Kelly-Sullivan DM, and Black SC (2003) Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 462:125-132. (Pubitemid 36183743)
13. Kirkham TC (2005) Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol 16:297-313.
14. Kunos G and Tam J (2011) The case for peripheral CB1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol 163:1423-1431.
15. Li AP, Kaminski DL, and Rasmussen A (1995) Substrate of human hepatic cytochrome P450 3A4. Toxicology 104:1-8. (Pubitemid 26016371)
16. Miao Z, Scott DO, Griffith DA, Day R, and Prakash C (2011) Excretion, metabolism, and pharmacokinetics of CP-945,598, a selective cannabinoid receptor antagonist, in rats, mice, and dogs. Drug Metab Dispos 39:2191-2208.
17. Nogueiras R, Diaz-Arteaga A, Lockie SH, Velásquez DA, Tschop J, López M, Cadwell CC, Diéguez C, and Tschöp MH (2009) The endocannabinoid system: role in glucose and energy metabolism. Pharmacol Res 60:93-98.
18. Omura T and Sato R (1964) The carbon monoxide binding pigment of liver microsomes. J Biol Chem 239:3137-3142.
19. Pagotto U, Marsicano G, Cota D, Lutz B, and Pasquali R (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27:73-100. (Pubitemid 43228239)
20. Prakash C, Shaffer CL, and Nedderman A (2007) Analytical strategies for identifying drug metabolites. Mass Spectrom Rev 26:340-369. (Pubitemid 46750374)
21. Ragan JA, Bourassa DE, Blunt J, Breen D, Busch FR, Cordi EM, Damon DB, Do N, Engtrakul A, Lynch D, et al. (2009) Development of a practical and efficient synthesis of CP-945598-01, a CB1 antagonist for the treatment of obesity. Org Process Res Dev 13:186-197.
22. Richard D and Boisvert P (2006) The endocannabinoid system and its role in energy homeostasis and abdominal obesity management. Int Obes 30:S1-S2.
23. Roffey SJ, Obach RS, Gedge JI, and Smith DA (2007) What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17-43.
24. Sun H and Scott DO (2010) Structure-based drug metabolism predictions for drug design. Chem Biol Drug Des 75:3-17.
25. Sun H and Scott DO (2011) Metabolism of 4-aminopiperidine drugs by cytochrome P450s: molecular and quantum mechanical insights into drug design. ACS Med Chem Lett 2:638-643.
26. Sun H, Ehlhardt WJ, Kulanthaivel P, Lanza DL, Reilly CA, and Yost GS (2007) Dehydrogenation of indoline by cytochrome P450 enzymes: a novel "aromatase" process. J Pharmacol Exp Ther 322:843-851. (Pubitemid 47105800)
27. Sun H, Moore C, Dansette PM, Kumar S, Halpert JR, and Yost GS (2009a) Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1- indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions. Drug Metab Dispos 37:672-684.
28. Sun H, Sharma R, Bauman J, Walker DP, Aspnes GE, Zawistoski MP, and Kalgutkar AS (2009b) Differences in CYP3A4 catalyzed bioactivation of 5-aminooxindole and 5-aminobenzsultam scaffolds in proline-rich tyrosine kinase 2 (PYK2) inhibitors: retrospective analysis by CYP3A4 molecular docking, quantum chemical calculations and glutathione adduct detection using linear ion trap/orbitrap mass spectrometry. Bioorg Med Chem Lett 19:3177-3182.
29. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA (2003) Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berlin) 167:103-111. (Pubitemid 36535298)
30. Wiley JL, Burston JJ, Leggett DC, Alekseeva OO, Razdan RK, Mahadevan A, and Martin BR (2005) CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 145:293-300. (Pubitemid 40896074)
31. Wrighton SA, VandenBranden M, and Ring BJ (1996) The human drug metabolizing cytochrome P450. J Pharmacokinet Biopharmacol 24:461-473. (Pubitemid 27156932)
32. Zhao Y, Hull AK, Gupta NR, Goss KA, Alonso J, Ecker JR, Normanly J, Chory J, and Celenza JL (2002) Trp-dependent auxin biosynthesis in Arabidopsis: involvement of cytochrome P450s CYP79B2 and CYP79B3. Genes Dev 16:3100-3112. (Pubitemid 35424196)